Table 1 Patients’ clinical characteristics
From: Prediction of abnormal bone mass with a pericoronary adipose tissue Attenuation model
Baseline characteristics | Training cohort (n = 217) | Internal validation cohort (n = 94) | External validation cohort (n = 50) | p value |
|---|---|---|---|---|
Age, years | 60.05 ± 11.42 | 59.53 ± 11.25 | 59.90 ± 9.32 | 0.932 |
Male | 132 (0.61) | 59 (0.63) | 23 (0.46) | 0.115 |
BMI, kg/m2 | 24.82 ± 3.24 | 25.22 ± 3.75 | 24.86 ± 3.59 | 0.628 |
Smoking | 74 (0.34) | 36 (0.37) | 17 (0.34) | 0.860 |
Drinking | 80 (0.37) | 38 (0.40) | 19 (0.38) | 0.876 |
Hypertension | 122 (0.56) | 57 (0.61) | 25 (0.50) | 0.463 |
CAD-RADS category | Â | Â | Â | 0.055 |
CAD-RADS ≤ 2 | 87 (0.40) | 42 (0.39) | 29 (0.58) |  |
CAD-RADS >2 | 130 (0.60) | 57 (0.61) | 21 (0.42) | Â |
Diabetes | 61 (0.28) | 28 (0.30) | 16 (0.32) | 0.850 |
Microvascular complications | 35 (0.16) | 10 (0.11) | 5 (0.10) | 0.252 |
Statins | 106 (0.49) | 50 (0.53) | 26 (0.52) | 0.760 |
Diuretics | 19 (0.09) | 6 (0.06) | 1 (0.02) | 0.236 |
β-blockers | 39 (0.18) | 11 (0.12) | 8 (0.16) | 0.419 |
CCB | 43 (0.20) | 23 (0.24) | 9 (0.18) | 0.603 |
ACEI | 56 (0.26) | 21 (0.22) | 10 (0.20) | 0.620 |
Insulins | 15 (0.07) | 6 (0.06) | 1 (0.02) | 0.270 |
Insulin secreting agent | 15 (0.07) | 2 (0.02) | 6 (0.12) | 0.088 |
Biguanides | 26 (0.12) | 11 (0.12) | 7 (0.14) | 0.925 |
α-Glucosidase inhibitors | 13 (0.06) | 2 (0.02) | 2 (0.04) | 0.220 |
SGLT-2 inhibitors | 13 (0.06) | 3 (0.03) | 2 (0.04) | 0.249 |
Dyslipidemia | 111 (0.51) | 58 (0.62) | 28 (0.56) | 0.196 |
GLU, mmol/L | 6.06 ± 2.46 | 5.80 ± 2.10 | 6.22 ± 2.31 | 0.545 |
Ca, mmol/L | 2.26 ± 0.14 | 2.25 ± 0.13 | 2.26 ± 0.14 | 0.877 |
P, mmol/L | 1.16 ± 0.20 | 1.17 ± 0.16 | 1.16 ± 0.16 | 0.938 |